Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.49%
0%
10.49%
6 Months
-15.75%
0%
-15.75%
1 Year
-49.7%
0%
-49.7%
2 Years
-28.98%
0%
-28.98%
3 Years
-11.55%
0%
-11.55%
4 Years
-81.36%
0%
-81.36%
5 Years
-77.23%
0%
-77.23%
Sensorion SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-197.51%
EBIT to Interest (avg)
-24.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
0
Tax Ratio
14.81%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.94
EV to EBIT
-1.82
EV to EBITDA
-1.88
EV to Capital Employed
5.58
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-307.23%
ROE (Latest)
-49.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-27.00
-27.30
1.10%
Interest
0.20
0.20
Exceptional Items
0.00
0.00
Consolidate Net Profit
-22.10
-23.20
4.74%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 4.74% vs -53.64% in Dec 2022
About Sensorion SA 
Sensorion SA
Pharmaceuticals & Biotechnology
Sensorion SA is a France-based company principally engaged in the biopharmaceutical sector. The Company is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The Company develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
Company Coordinates 
Company Details
375, rue du Professeur Joseph Blayac , MONTPELLIER None : 34080
Registrar Details






